Literature DB >> 16079113

European consensus on grading bone marrow fibrosis and assessment of cellularity.

Jürgen Thiele1, Hans Michael Kvasnicka, Fabio Facchetti, Vito Franco, Jon van der Walt, Attilio Orazi.   

Abstract

Quantification of characteristic bone marrow biopsy features includes basic parameters such as cellularity and fiber content. These are important to assess the dynamics of disease processes with a significant impact on risk stratification, survival patterns and, especially, therapy-related changes. A panel of experienced European pathologists and a foreign expert evaluated, at a multi-headed microscope, a large number of representative slides of trephine biopsies from patients with myelofibrosis in an attempt to reach a consensus on how to grade cellularity and fibrosis. This included a critical evaluation of previously described scoring systems. During the microscopic analysis and subsequent discussion and voting, the importance of age-dependent decrease in cellularity was recognized. Grading of myelofibrosis was simplified by using four easily reproducible categories including differentiation between reticulin and collagen. A consensus was reached that the density of fibers must be assessed in relation to the hematopoietic tissue. This feature is especially important in order to avoid a false impression of a reduced fiber content in fatty and/or edematous bone marrow samples after treatment. The consensus for measuring myelofibrosis by clear and reproducible guidelines achieved by our group should allow for precise grading during the disease process and after therapy.

Entities:  

Mesh:

Year:  2005        PMID: 16079113

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  214 in total

1.  p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Authors:  Leonie Saft; Mohsen Karimi; Mehran Ghaderi; András Matolcsy; Ghulam J Mufti; Austin Kulasekararaj; Gudrun Göhring; Aristoteles Giagounidis; Dominik Selleslag; Petra Muus; Guillermo Sanz; Moshe Mittelman; David Bowen; Anna Porwit; Tommy Fu; Jay Backstrom; Pierre Fenaux; Kyle J MacBeth; Eva Hellström-Lindberg
Journal:  Haematologica       Date:  2014-03-28       Impact factor: 9.941

2.  CD133 marks a stem cell population that drives human primary myelofibrosis.

Authors:  Ioanna Triviai; Thomas Stübig; Birte Niebuhr; Kais Hussein; Asterios Tsiftsoglou; Boris Fehse; Carol Stocking; Nicolaus Kröger
Journal:  Haematologica       Date:  2015-02-27       Impact factor: 9.941

3.  Angiogenesis and survival in patients with myelodysplastic syndrome.

Authors:  Aleksandar Savic; Vesna Cemerikic-Martinovic; Sinisa Dovat; Nebojsa Rajic; Ivana Urosevic; Borivoj Sekulic; Vanja Kvrgic; Stevan Popovic
Journal:  Pathol Oncol Res       Date:  2012-01-24       Impact factor: 3.201

Review 4.  Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

5.  Efficacy of ALK5 inhibition in myelofibrosis.

Authors:  Lanzhu Yue; Matthias Bartenstein; Wanke Zhao; Wanting Tina Ho; Ying Han; Cem Murdun; Adam W Mailloux; Ling Zhang; Xuefeng Wang; Anjali Budhathoki; Kith Pradhan; Franck Rapaport; Huaquan Wang; Zonghong Shao; Xiubao Ren; Ulrich Steidl; Ross L Levine; Zhizhuang Joe Zhao; Amit Verma; Pearlie K Epling-Burnette
Journal:  JCI Insight       Date:  2017-04-06

6.  Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.

Authors:  Cecilia Arana Yi; Ghayathri Jeyakumar; Pedro Medina; Jorge Cortes; Sherry Pierce; Carlos Bueso-Ramos; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-11-13       Impact factor: 3.156

7.  Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7.

Authors:  Elena Crisà; Austin G Kulasekararaj; Vera Adema; Esperanza Such; Julie Schanz; Detlef Haase; Katayoon Shirneshan; Steven Best; Syed A Mian; Aytug Kizilors; José Cervera; Nicholas Lea; Dario Ferrero; Ulrich Germing; Barbara Hildebrandt; Ana Belén Valencia Martínez; Valeria Santini; Guillermo F Sanz; Francesc Solé; Ghulam J Mufti
Journal:  Leukemia       Date:  2020-02-17       Impact factor: 11.528

8.  Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.

Authors:  Anthony D Pomicter; Anna M Eiring; Anna V Senina; Matthew S Zabriskie; James E Marvin; Josef T Prchal; Thomas O'Hare; Michael W Deininger
Journal:  Exp Hematol       Date:  2015-04-24       Impact factor: 3.084

Review 9.  Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.

Authors:  Donal P McLornan; Juan Carlos Hernandez Boluda; Tomasz Czerw; Nicholas Cross; H Joachim Deeg; Marcus Ditschkowski; Mufaddal T Moonim; Nicola Polverelli; Marie Robin; Mahmoud Aljurf; Eibhlin Conneally; Patrick Hayden; Ibrahim Yakoub-Agha
Journal:  Leukemia       Date:  2021-05-26       Impact factor: 11.528

10.  Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis.

Authors:  Marko Lucijanic; Davor Galusic; Ivan Krecak; Martina Sedinic; Hrvoje Holik; Vlatka Perisa; Martina Moric Peric; Ivan Zekanovic; Tajana Stoos-Veic; Rajko Kusec
Journal:  Ann Hematol       Date:  2020-08-29       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.